|
|
Article: Introgen's INGN 241 Cancer Therapy Triggers Immune System to Kill Cancer Cells.
- Article from:
- PR Newswire
- Article date:
- July 21, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
New Data Published in Journal of Leukocyte Biology
AUSTIN, Texas, July 21 /PRNewswire-FirstCall/ -- Researchers at Introgen Therapeutics, Inc. and their collaborators at The University of Texas M. D. Anderson Cancer Center have published new findings on the role of IL-24 in regulating the immune system in the current online issue of the Journal of Leukocyte Biology. MDA-7/IL-24 is the active component of INGN 241, an investigational cancer therapy currently in a Phase 2 trial in patients with malignant melanoma. A growing body of preclinical and clinical data indicates that INGN 241 stimulates the immune system to attack cancer cells through IL-24-dependent ...